CN116058496B - Composite tartary buckwheat instant tablet and production method thereof - Google Patents

Composite tartary buckwheat instant tablet and production method thereof Download PDF

Info

Publication number
CN116058496B
CN116058496B CN202211145004.XA CN202211145004A CN116058496B CN 116058496 B CN116058496 B CN 116058496B CN 202211145004 A CN202211145004 A CN 202211145004A CN 116058496 B CN116058496 B CN 116058496B
Authority
CN
China
Prior art keywords
tartary buckwheat
parts
instant
powder
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202211145004.XA
Other languages
Chinese (zh)
Other versions
CN116058496A (en
Inventor
钱咏邠
田益玲
武升阳
李慧静
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hebei Longhe Noodles Co ltd
Original Assignee
Hebei Longhe Noodles Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hebei Longhe Noodles Co ltd filed Critical Hebei Longhe Noodles Co ltd
Priority to CN202211145004.XA priority Critical patent/CN116058496B/en
Publication of CN116058496A publication Critical patent/CN116058496A/en
Application granted granted Critical
Publication of CN116058496B publication Critical patent/CN116058496B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
    • A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
    • A23L25/30—Mashed or comminuted products, e.g. pulp, pastes, meal, powders; Products made therefrom, e.g. blocks, flakes, snacks; Liquid or semi-liquid products
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/104—Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/117—Flakes or other shapes of ready-to-eat type; Semi-finished or partly-finished products therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/161—Puffed cereals, e.g. popcorn or puffed rice
    • A23L7/165—Preparation of puffed cereals involving preparation of meal or dough as an intermediate step
    • A23L7/17—Preparation of puffed cereals involving preparation of meal or dough as an intermediate step by extrusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/52—Juglandaceae (Walnut family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/894—Dioscoreaceae (Yam family)
    • A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8969—Polygonatum (Solomon's seal)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/90—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in food processing or handling, e.g. food conservation

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a composite tartary buckwheat instant tablet and a production method thereof, wherein the composite tartary buckwheat instant tablet comprises the following raw materials in parts by weight: 250-350 parts of tartary buckwheat instant tablet base powder, 25-25 parts of microcrystalline fiber, 20-28 parts of isomaltulose, 15-23 parts of fructo-oligosaccharide, 10-18 parts of tartary buckwheat whole plant fermentation liquor, 2-6 parts of isomaltooligosaccharide, 2-6 parts of galactosyl mannose, 0.5-1.5 parts of aloe gel, 0.5-1.5 parts of astragalus gel and 0.2-0.7 part of transparent sodium phytate. The production method comprises the following steps: uniformly mixing tartary buckwheat rice, tartary buckwheat roots and tartary buckwheat leaves, and obtaining a tartary buckwheat whole plant fermentation liquor by adopting a microwave extraction method; mixing radix Et rhizoma Fagopyri Tatarici powder, semen Setariae powder, fructus Cucurbitae moschatae powder, fructus Momordicae Charantiae powder, radix Glycyrrhizae, poria, and rhizoma Polygonati, adding water, extruding, puffing, aging, and pulverizing to obtain radix Et rhizoma Fagopyri Tatarici instant tablet base powder; and then uniformly mixing the raw materials of the instant tartary buckwheat tablet, tabletting and drying to prepare a finished product. The invention solves the problem of heavier bitter taste in the eating of the tartary buckwheat by adopting a modern processing technology, and utilizes the raw materials with homology of medicine and food to optimize the formula so as to effectively regulate the blood pressure.

Description

Composite tartary buckwheat instant tablet and production method thereof
Technical Field
The invention relates to the technical field of agricultural product deep processing, in particular to a compound tartary buckwheat instant tablet and a production method thereof.
Background
In recent years, with the continuous development of economy, the living standard of people is continuously improved, and a series of 'rich diseases' which are difficult to radically cure, such as diabetes, hypertension and the like, are induced. The tartary buckwheat has the health care functions of resisting tumor, resisting cancer, reducing blood sugar, reducing blood fat, reducing blood pressure and the like, and meets the requirements of wide consumers, especially 'three-high' people, on nutritional health food. Therefore, the development of the tartary buckwheat industry is imperative, and the development trend of society is also met. At present, the tartary buckwheat products in the consumer market in China are single in variety, cannot be produced and processed in scale, are low in development degree, and are few in types of deep processed products. In addition, because the tartary buckwheat has bitter taste and is influenced by regional eating habits, most consumers lose the purchasing desire of the tartary buckwheat and the products thereof. In addition, the common tartary buckwheat tea product has one-way blood pressure reduction due to tartary buckwheat, and hypotension is often caused by excessive eating.
Disclosure of Invention
In view of the above, the invention provides a compound tartary buckwheat instant tablet and a production method thereof. The invention solves the problem of heavier bitter taste in the eating of the tartary buckwheat by adopting the modern processing technology, improves the flavor of the tartary buckwheat, fully utilizes the raw materials with homology of medicine and food, optimizes the formula and develops the tartary buckwheat instant tablet which takes the tartary buckwheat raw materials as the main material and can effectively regulate the blood pressure.
In order to achieve the above purpose, the invention adopts the following technical scheme:
a composite instant tartary buckwheat tablet comprises the following raw materials in parts by weight: 250-350 parts of tartary buckwheat instant tablet base powder, 25-35 parts of microcrystalline fiber, 20-28 parts of isomaltulose, 15-23 parts of fructo-oligosaccharide, 10-18 parts of tartary buckwheat whole plant fermentation liquor, 2-6 parts of isomaltooligosaccharide, 2-6 parts of galactosyl mannose, 0.5-1.5 parts of aloe gel, 0.5-1.5 parts of astragalus gel and 0.2-0.7 part of transparent sodium phytate.
Further, the tartary buckwheat instant tablet base powder comprises the following components in parts by weight: 15-25 parts of tartary buckwheat powder, 5-15 parts of millet powder, 3-8 parts of pumpkin powder, 3-8 parts of bitter gourd powder, 1-3 parts of liquorice, 1-3 parts of poria cocos and 0.5-1.5 parts of rhizoma polygonati.
Further, the whole tartary buckwheat strain fermentation broth comprises the following raw materials in parts by weight: 4 to 6 parts of tartary buckwheat rice, 1.5 to 2.5 parts of tartary buckwheat root and 0.5 to 1.5 parts of tartary buckwheat leaf.
The invention also provides a production method of the composite tartary buckwheat instant tablet, which comprises the following steps:
step 1, preparing a whole tartary buckwheat strain fermentation liquor; mixing semen Fagopyri Esculenti, radix Et rhizoma Fagopyri Tatarici and folium Et rhizoma Fagopyri Tatarici, pulverizing, adding Aspergillus niger, yeast and lactobacillus, fermenting for 24-30 days to obtain radix Et rhizoma Fagopyri Tatarici whole plant fermentation broth;
step 2, preparing the tartary buckwheat instant tablet base powder: mixing radix Et rhizoma Fagopyri Tatarici powder, semen Setariae powder, fructus Cucurbitae moschatae powder, fructus Momordicae Charantiae powder, radix Glycyrrhizae, poria, rhizoma Polygonati, adding water, extruding, puffing, aging, and pulverizing to obtain radix Et rhizoma Fagopyri Tatarici instant tablet base powder;
step 3, preparation of tartary buckwheat instant tablets: mixing instant radix Et rhizoma Fagopyri Tatarici tablet base powder, microcrystalline cellulose, isomaltulose, fructooligosaccharide, radix Et rhizoma Fagopyri Tatarici whole plant fermentation broth, isomaltooligosaccharide, galactosyl mannose, aloe gum, tragacanth, and sodium hyaluronate, adding water, shaping, slicing, and drying.
Further, the step 1 is to mix the tartary buckwheat rice, the tartary buckwheat root and the tartary buckwheat leaf uniformly, crush the mixture, sieve the mixture with 10 to 30 meshes, add 1 to 3 weight percent of aspergillus niger, 3 to 9 weight percent of yeast and 0.2 to 0.3 weight percent of lactobacillus and ferment for 24 to 30 days.
Further, the step 2 is carried out extrusion, expansion and curing by using a screw extrusion and expansion machine, the screw rotation speed of the screw extrusion and expansion machine is 250-350 r/min, the extrusion temperature is 150-200 ℃, the water content of the materials is controlled to be 20-30%, and the gelatinization degree of the product is 90% -95%.
The invention has the beneficial effects that:
1) Tartary buckwheat is also a common food with homology of medicine and food, and has the effects of tonifying qi, replenishing spirit, benefiting eyes, reducing qi, and widening intestines as long as the description of the flavor of the tartary buckwheat is flat and cold in nature in Li Shi Zhi in Ben Cao gang mu. Therefore, the tartary buckwheat is also an effective food for regulating spleen and stomach stagnation and can lower qi to remove the spleen and stomach stagnation. Especially for phlegm dampness and turbid phlegm in spleen and stomach, tartary buckwheat also has certain effect. However, fagopyrum tataricum is cold in nature and bitter in taste, so people with deficiency-cold spleen and stomach cannot eat the Fagopyrum tataricum. Plum fruit, fructus Foeniculi, and fructus Foeniculi should be used with cautions for people with deficiency-cold spleen and stomach. The Chinese yam and walnut in the formula of the invention strengthen spleen and replenish qi, warm yang and dispel cold; millet has effects of invigorating spleen and stomach, tonifying kidney, nourishing heart and tranquilizing. Poria is sweet and light in taste, mild in nature and nontoxic, enters four channels of heart, spleen, lung and kidney, and has the effects of excreting dampness and promoting diuresis, tonifying spleen and stomach and protecting kidney, soothing nerves and promoting fluid production and the like. Licorice root, radix Glycyrrhizae Praeparata, which regulates the cold, heat, yin and yang in the recipe, is beneficial to the health of eaters.
2) The formula enriches flavone in the tartary buckwheat, not only strengthens the blood pressure reducing function, but also fundamentally eliminates deposited lipoprotein in blood vessels, and fundamentally solves the problem of high blood pressure. The immunity of the eaters can be effectively improved due to the combined action of various raw materials, and the Chinese herbal medicine composition has good effects on the current diseases such as three highs and the like;
3) The product prepared by the invention breaks through the traditional tartary buckwheat eating method and is convenient to eat.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings that are required to be used in the embodiments or the description of the prior art will be briefly described below, and it is obvious that the drawings in the following description are only embodiments of the present invention, and that other drawings can be obtained according to the provided drawings without inventive effort for a person skilled in the art.
FIG. 1 is a drawing showing a Tartary buckwheat tablet prepared in example 1 of the present invention.
Detailed Description
The following description of the technical solutions in the embodiments of the present invention will be clear and complete, and it is obvious that the described embodiments are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Example 1
Production method of composite tartary buckwheat instant tablet
Step 1, preparing a whole tartary buckwheat strain fermentation liquor; mixing radix Et rhizoma Fagopyri Tatarici 5 parts, radix Et rhizoma Fagopyri Tatarici 2 parts and radix Et rhizoma Fagopyri Tatarici leaf 1 parts, pulverizing, sieving with 20 mesh sieve, soaking for 14min, adding Aspergillus niger 1wt%, yeast 9wt% and lactobacillus 0.2wt% and fermenting for 24 days to obtain radix Et rhizoma Fagopyri Tatarici whole plant fermentation broth;
step 2, preparing the tartary buckwheat instant tablet base powder: 20 parts of tartary buckwheat powder, 10 parts of millet powder, 5 parts of pumpkin powder, 5 parts of balsam pear powder, 4 parts of Chinese yam powder, 3 parts of walnut powder, 2 parts of liquorice, 2 parts of poria cocos and 1 part of rhizoma polygonati are uniformly mixed, and 20 parts of water is added for extrusion, puffing and curing, and then crushing is carried out, so that tartary buckwheat instant tablet base powder is prepared;
step 3, preparation of tartary buckwheat instant tablets: mixing 300 parts of instant tartary buckwheat tablet base powder, 28 parts of microcrystalline fiber, 25 parts of isomaltulose, 20 parts of fructooligosaccharide, 16 parts of tartary buckwheat whole plant fermentation liquor, 5 parts of isomaltooligosaccharide, 5 parts of galactosyl mannose, 0.8 part of aloe gel, 0.8 part of astragalus gum and 0.4 part of transparent sodium phytate; 100 parts of mixed powder is obtained, 28 parts of water is added into the mixed powder to be stirred and used, a self-made compression roller is used for calendaring into slices, and then the slices are cut into slices and dried to obtain the finished product.
Example 2
Production method of composite tartary buckwheat instant tablet
Step 1, preparing a whole tartary buckwheat strain fermentation liquor; mixing 7 parts of tartary buckwheat rice, 3 parts of tartary buckwheat roots and 2 parts of tartary buckwheat leaves uniformly, crushing, sieving with a 20-mesh sieve, soaking for 14min, and adding 2wt% of aspergillus niger, 6wt% of yeast and 0.3wt% of lactobacillus for fermenting for 30 days;
step 2, preparing the tartary buckwheat instant tablet base powder: 19 parts of tartary buckwheat powder, 8 parts of millet powder, 4 parts of pumpkin powder, 4 parts of balsam pear powder, 4 parts of yam powder, 2 parts of walnut powder, 2 parts of liquorice, 3 parts of poria cocos, and 0.8 part of rhizoma polygonati are uniformly mixed, and 23 parts of water is added for extrusion, puffing and curing, and then crushing is carried out, so as to prepare tartary buckwheat instant tablet base powder;
step 3, preparation of tartary buckwheat instant tablets: mixing 320 parts of tartary buckwheat instant tablet base powder, 30 parts of microcrystalline fiber, 24 parts of isomaltulose, 18 parts of fructooligosaccharide, 14 parts of tartary buckwheat whole plant fermentation liquor, 4 parts of isomaltooligosaccharide, 4 parts of galactosyl mannose, 1 part of aloe vera gel, 1 part of tragacanth gel and 0.5 part of sodium hyaluronate; 100 parts of mixed powder is obtained, 18-22 parts of water is added into the mixed powder to be stirred for uniform use, the mixed powder is rolled into a sheet by a self-made compression roller, and then the sheet is sliced and dried to obtain a finished product.
Test examples
1 Fagopyrum tataricum instant tablet prepared in example 1 blood pressure reducing test
Test animals
Weight 220-240 g,30 SPF grade male Spontaneous Hypertension Rats (SHR), 12 male Wistar-Kyoto (WKY) rats were purchased from Beijing Vitre Lihua laboratory animal technologies Co.
Group of test animals and dose setting
The feeding environment is 25+/-1 ℃, the relative humidity is 55% -65%, the day and night light and shade are alternated, the feeding and drinking water are carried out independently, and after the feeding is carried out for 1 week, the gastric lavage test is carried out. Crushing the instant tartary buckwheat slices into powder, weighing 6g, adding 100mL of distilled water at 100 ℃, heating in a boiling water bath for 30min, filtering, steaming in a rotary manner, and redissolving with 100mL of distilled water to obtain 60g/L tea extract. Each group of rats was regulated to 1mL/100g gastric lavage volume. Before the test, the blood pressure of the rats was measured every other day, and the test was started after stable adaptation. The blood pressure of the spontaneous hypertension rat before administration was measured after the adaptive feeding, measured again after the interval of 2d, and the average value was taken 3 times repeatedly as an initial value before administration. The test groups measured systolic and diastolic blood pressure of spontaneous hypertensive rats at 2,4,6, 12, 24 hours after administration, respectively.
30 SHRs were randomly divided into 5 groups (6 per group): a tartary buckwheat instant tablet high dose group, a tartary buckwheat instant tablet medium dose group, a tartary buckwheat instant tablet low dose group, a tartary buckwheat instant tablet model control group and a tartary buckwheat instant tablet positive control group; 12 WKY rats were randomly divided into 2 groups (6 per group): normal control group, normal high dose group. High dose group (SHR-H) of instant tartary buckwheat tablet, 600mg/kg; medium dose group (SHR-M), 300mg/kg; low dose group (SHR-L), 100mg/kg; model control group (SHR-NaCl), corresponding dose of physiological saline; a positive control group (SHR-captopril), wherein the dosage of captopril is 1mg/kg according to daily dosage of human body through body surface area conversion; normal high dose group (WKY-H), 600mg/kg; normal control group (WKY), corresponding dose of physiological saline.
Table 1 influence of each test group on spontaneous hypertension rat tail artery systolic blood pressure
Before comparative administration, P is less than 0.05; comparing WKY group, wherein the number of the groups is less than 0.05; and (3) comparing the model group, wherein delta is P < 0.05.
TABLE 2 influence of test groups on the diastolic blood pressure of the tail artery of spontaneously hypertensive rats
Before comparative administration, P is less than 0.05; comparing WKY group, wherein the number of the groups is less than 0.05; and (3) comparing the model group, wherein delta is P < 0.05.
As can be seen from Table 1, the effect of administration on the systolic blood pressure of rat tail with spontaneous hypertension was that SHR-captopril group was maximally reduced by (2.81.+ -. 0.57) kPa compared to SHR-NaCl group after 4 hours of administration; SHR systolic blood pressure was reduced (2.48±0.44) kPa after gavage compared to that before administration. The minimum systolic blood pressure value was reached after 6H of gastric lavage in the SHR-H group, which was reduced by (2.42.+ -. 0.22) kPa compared to the SHR-NaCl group and by (2.14.+ -. 0.56) kPa compared to the pre-administration group. Unlike the SHR-H group, the SHR-M group showed an increase in blood pressure after 2 hours of gastric lavage, and then reached the minimum systolic pressure after 6 hours of gastric lavage, reduced (1.20.+ -. 0.27) kPa compared to the control group, and reduced (1.28.+ -. 0.27) kPa before administration compared to the SHR-M group at 6 hours. The overall blood pressure reducing effect of the SHR-M group is weaker than that of the SHR-H group, and the contraction pressure also returns to the initial blood pressure before administration after the gastric lavage for 24 hours. The SHR-L group of rats showed a state of agitation, which is a good condition, compared with other lavage groups. The systolic pressure of the SHR-L group starts to be obviously reduced after the gastric lavage for 4 hours, and reaches the maximum depressurization effect at 12 hours, which is reduced by (1.17+/-0.27) kPa compared with the SHR-NaCl group, is reduced by (1.24+/-0.14) kPa at the time of the gastric lavage for 6 hours compared with the prior administration, and the depressurization effect is similar to that of the SHR-M group. The result shows that the blood pressure reducing effect of the captopril after the stomach filling can be maintained for 18 to 20 hours, the SHR-H group can be maintained for 6 to 12 hours, the SHR-M group can be maintained for 6 hours, and the SHR-L group can be maintained for about 8 hours. Along with the increase of the stomach irrigation concentration of the instant tartary buckwheat tablet, the reduction amplitude of the systolic pressure of the SHR rat also becomes larger, which shows that the blood pressure reducing effect has a certain correlation with the concentration of the tartary buckwheat. As can be seen from Table 2, the SHR-captopril group decreased (1.94.+ -. 0.15) kPa at 12 hours of gastric lavage, the SHR-H group decreased (0.88.+ -. 0.40) kPa at 6 hours of gastric lavage, the SHR-H group decreased (0.66.+ -. 0.40) kPa at 6 hours of gastric lavage, and maintained at 12 hours, and the SHR-L group had a weaker diastolic blood pressure decreasing effect, but also decreased (0.49.+ -. 0.63) kPa at 6 hours of gastric lavage, as compared with the SHR-NaCl group systolic blood pressure. The diastolic pressure of SHR-H group and SHR-L group at intragastric period of 12H is significantly higher than that of SHR-captopril group compared with the positive control group. Compared with the prior administration, the SHR-captopril group obviously reduces the SHR diastolic pressure, the effect is the most obvious in the 4 administration groups, the SHR-H group obviously reduces in 4 hours of gastric lavage, the SHR-M group has obvious depressurization effect in 6 hours of gastric lavage, and the SHR-L group has no obvious diastolic pressure drop effect on the SHR in 24 hours of gastric lavage. The effect of the instant tartary buckwheat tablet on the diastolic blood pressure of the spontaneous hypertension rat is also dependent on the gastric lavage concentration, the higher the concentration is, the more obvious the effect of the diastolic blood pressure is, and the effect of captopril on improving the SHR diastolic blood pressure is superior to that of the instant tartary buckwheat tablet.
As can be seen from tables 1 and 2, compared with the administration period, the examination analysis shows that the WKY-H has no significant change in the diastolic pressure and the systolic pressure within 24 hours of the intragastric administration, and even though the intragastric administration is performed at a high dosage, the tablet basically maintains the normal diastolic pressure and the systolic pressure level in spite of the fluctuation trend, which indicates that the blood pressure of the normal rats is not greatly influenced by the instant tartary buckwheat tablet. And for people with normal blood pressure, the problem of hypotension is easy to cause when the tartary buckwheat is taken alone.
2 lipid-lowering test of Tartary buckwheat instant tablet prepared in example 1
2.1 Experimental materials
Instant tartary buckwheat tablet and tartary buckwheat
Experimental animals: SPF grade 60 healthy male KM mice with a body mass of 18-22g are provided by Experimental animal center of Hebei university of medical science.
Reagent: propylthiouracil, lard, cholesterol, tween-80, propylene glycol, sodium deoxycholate
The kit comprises: total Cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), coomassie Brilliant protein (Coomassie blue protein), malondialdehyde (MDA), superoxide dismutase (SOD) and reduced Glutathione (GSH) determination kit, nanjing is built into the bioengineering institute.
2.2 laboratory apparatus
Analytical balance, electronic balance, quick mixer, digital display water bath kettle and high-speed centrifuge
2.3 Experimental methods
2.3.1 experimental animals group: the experimental animals are divided into 5 groups, namely a normal control group, a high-fat model group, a tartary buckwheat low-dose group, a tartary buckwheat medium-dose group and a tartary buckwheat high-dose group, and each group comprises 12 mice.
2.3.2 preparation and dose setting of the tartary buckwheat instant tablet medicament:
grinding and pulverizing instant radix Et rhizoma Fagopyri Tatarici, dissolving with distilled water as much as possible, and mixing.
Low dose: 200 mg/kg.d (300 mg instant tartary buckwheat tablet is dissolved in 30ml distilled water);
medium dose: 400 mg/kg.d (600 mg instant tartary buckwheat tablet is dissolved in 30ml distilled water);
high dose: 800mg/kg d (1200 mg instant tartary buckwheat tablet is dissolved in 30ml distilled water)
2.3.3 preparation of fat emulsion:
1g of propylthiouracil is ground in a mortar and stored in another container for later use. Melting 20g lard in 40 deg. water bath, placing in a mortar, adding 10g cholesterol and 1g propylthiouracil, stirring thoroughly, and dissolving. Then adding 20mL of Tween-80 and 20mL of propylene glycol respectively, grinding and mixing uniformly, then slowly adding 20mL of 10% deoxycholate sodium aqueous solution, grinding and emulsifying. Distilled water was further added to 100mL. Putting into a closed container, refrigerating, and melting in water bath at 37deg.C.
2.3.4 test method:
after the mice are adaptively raised for 5 days, weighing, filling the stomach distilled water of a blank control group in the morning of 0.2mL/10g each day, filling the stomach fat emulsion of the other groups in the morning of 0.1mL/10g each day, filling the stomach distilled water of a blank control group in the afternoon and a high-fat model group in the afternoon of 0.2mL/10g, filling the stomach with low, medium and high dosage tartary buckwheat instant tablet medicaments in the other groups in the 3 groups according to the equal volume of 0.2mL/10g, continuously feeding the test objects for 8 weeks, and recording the weight each week; after the last administration, the medicine is fasted for 16 hours, the orbit is taken out of blood, the medicine is split into two centrifuge tubes, one centrifuge tube is used for centrifuging, the serum is taken out of the centrifuge tube to measure the blood lipid index, and the other centrifuge tube is used for measuring the antioxidant index of the whole blood. After blood collection, mice were sacrificed for cervical dislocation, livers were isolated and weighed. Taking 0.2g liver, placing in 1.8ml physiological saline, homogenizing, and measuring antioxidant index of liver tissue.
2.4 principle of experimental determination
2.4.1 Molding
Principle of: the fat emulsion containing cholesterol, lard and sodium cholate is used for lavaging the stomach of an experimental animal to form a fat metabolism disorder animal model, then a tested sample is given to the animal, the influence of the tested sample on hyperlipidemia can be detected, and the influence of the tested sample on lipid absorption, lipoprotein formation and lipid degradation or excretion can be judged.
2.4.2 reducing blood lipid:
(1) Principle of: hyperlipidemia induces an increase in body weight, serum total cholesterol, serum triglycerides, serum low-density lipoprotein cholesterol levels, and serum high-density lipoprotein cholesterol levels.
(2) And (3) observing the indexes: body weight, serum total cholesterol, serum triglycerides, serum high density lipoprotein cholesterol, serum low density lipoprotein cholesterol.
(3) Auxiliary blood lipid reduction function result judgment:
(1) compared with a blank control group, the model control group has the advantages that the serum triglyceride is increased, the serum total cholesterol or the low-density lipoprotein cholesterol is increased, the difference is obvious, and the model is judged to be established.
(2) And comparing each dose group with a model control group, wherein the serum total cholesterol or the low-density lipoprotein cholesterol of any dose group is reduced, the serum triglyceride of any dose group is reduced, the difference is obvious, and meanwhile, the serum high-density lipoprotein cholesterol of each dose group is not obviously lower than that of the model control group, so that the positive experimental result of the animal with the auxiliary blood lipid reducing function of the tested sample can be judged.
(3) And compared with a model control group, the serum total cholesterol or the low-density lipoprotein cholesterol of any dose group is reduced, the difference is significant, meanwhile, the serum triglyceride of each dose group is not significantly higher than the model control group, the serum high-density lipoprotein cholesterol of each dose group is not significantly lower than the model control group, and the positive test result of the animal with the function of reducing the serum cholesterol assisted by the tested sample can be judged.
(4) And compared with a model control group, the serum triglyceride of each dosage group is reduced, the difference is obvious, meanwhile, the serum total cholesterol and the low-density lipoprotein cholesterol of each dosage group are not obviously higher than those of the model control group, the serum high-density lipoprotein cholesterol is not obviously lower than those of the model control group, and the positive result of the experimental result of the animal with the function of auxiliary reduction of the serum triglyceride of the tested sample can be judged.
2.4.3 antioxidation:
(1) Principle of: malondialdehyde is one of the end products of peroxidation of cell membrane lipids, and the content of malondialdehyde can be measured to indirectly estimate the degree of peroxidation of the lipid, and the higher the content is, the higher the degree of oxidation is; SOD catalyzed superoxide anion radical (O) 2·- ) Generation of H 2 O 2 Then other antioxidant enzymes such as glutathione peroxidase (GSH-PX) and catalase react to produce water, so that O can be removed 2·- The toxic action on cells, the stronger the SOD activity, the stronger the antioxidant capacity; glutathione is a low molecular scavenger that scavenges O 2·- 、H 2 O 2 Etc. Glutathione is a tripeptide consisting of glutamic acid, glycine and cysteine, is a main non-protein sulfhydryl compound in tissues, is a substrate of two enzymes of GSH-PX (glutathione peroxidase) and GST (glutathione sulfhydryl transferase), is necessary for the two enzymes to decompose hydroperoxide, can stabilize sulfhydryl-containing enzymes and prevent hemoglobin and other auxiliary factors from oxidative damage, and the lack or the exhaustion of GSH can promote poisoning by a plurality of chemical substances or environmental factors, so that the amount of GSH is an important factor for measuring the oxidation resistance of organisms, and the higher the content is, the stronger the oxidation resistance is.
(2) And (3) observing the indexes:
body weight, malondialdehyde, superoxide dismutase, and reduced glutathione
(3) And (3) judging an antioxidant function result:
(1) the reduction of malondialdehyde content in the test sample group is statistically significant compared with the model control group, and the test sample is judged to have lipid peroxidation reduction effect, and the index result is positive.
(2) Comparing the tested sample group with the model control group, the SOD activity increase has statistical significance, and judging that the tested sample has the effect of increasing the antioxidant enzyme activity, and the index result is positive.
(3) And comparing the tested sample group with the model control group, wherein the GSH content increase has statistical significance, and judging that the tested sample has the effect of increasing the antioxidant substance GSH, and the index result is positive.
The three indexes are positive, and the test result of the antioxidant animal of the tested sample can be judged to be positive.
2.5, results and analysis
2.5.1 Effect of Tartary buckwheat instant tablet on body Mass and liver index of hyperlipidemic mice
As can be seen from table 3, after eight weeks of continuous gastric lavage, the weight gain rate of the mice in the model group was significantly different from that of the mice in the blank group (P < 0.01), and the weight gain rate of the mice in the model group was 8.47% higher than that of the mice in the blank group; the weight gain rate of the mice in the model group is extremely obviously different from that of the middle-and high-dose groups in the instant tartary buckwheat tablet (P is less than 0.01), and compared with the model group, the weight gain rate of the middle-and high-dose groups in the tartary buckwheat is obviously reduced by 6.02 percent and 10.03 percent respectively; the liver index of the mice in the model group was 0.57% higher than that of the blank group, and there was a very significant difference (P < 0.01); compared with the model group, the liver indexes of the instant tartary buckwheat tablet in low, medium and high dose groups are obviously reduced by 0.48%, 0.55% and 0.63%, and extremely significant differences (P < 0.01) exist. In the test process, the test object does not cause abnormal reactions such as diarrhea, vomiting and the like of the mice.
Table 3: influence of Tartary buckwheat instant tablet on mouse body quality and liver index
Note that: capitalized space represents the difference in significance at P < 0.05; the lowercase letter indicates a significant difference at P < 0.01. The same astronomical mother has no significant difference.
2.5.2 Effect of Tartary buckwheat instant tablet on hyperlipidemia mice blood lipid reduction
As can be seen from Table 4, after eight weeks of continuous gastric lavage, the model group showed significant differences (P < 0.05) in HDL-C, LDL-C, T-CHO and the control group showed significant differences (P < 0.01) in TG, and it was statistically significant to indicate successful molding.
The serum HDL-C level of the mice in the model group is lower than that of the mice in the middle-and high-dose groups of the instant tartary buckwheat slices, the significant difference (P < 0.05) is provided, and the significant difference (P < 0.05) is not provided between the mice in the middle-and high-dose groups of the instant tartary buckwheat slices, which indicates that the serum HDL-C content of the mice with hyperlipidemia in the instant tartary buckwheat slices is improved by the high dose groups, and the low dose of the tartary buckwheat has no significant influence on the content of the mice with hyperlipidemia; the serum LDL-C level of the mice in the model group is not significantly different from that of the instant tartary buckwheat tablet in low, medium and high dose groups (P < 0.01), which shows that the instant tartary buckwheat tablet has no significant effect on the serum LDL-C content in the mice with hyperlipidemia; the serum TG level of the mice in the model group is obviously higher than that of the mice in the low, medium and high dose groups of the instant tartary buckwheat slices, and has extremely obvious difference (P is less than 0.01), which indicates that the instant tartary buckwheat slices have obvious effect on reducing the serum TG level of the mice with hyperlipidemia; compared with a model group, the serum T-CHO of the middle-dose and high-dose groups of the tartary buckwheat is obviously reduced, has extremely obvious difference (P < 0.01), and has no obvious difference (P < 0.05) with the low-dose groups of the tartary buckwheat, which shows that the middle-dose and high-dose of the tartary buckwheat instant tablet has the effect of reducing the serum T-CHO of the mice with hyperlipidemia, and the influence of the low-dose of the tartary buckwheat on the content of the tartary buckwheat is not obvious.
Compared with the mice in the blank control group, the serum HDL-C, TG content of the instant tartary buckwheat slices in the low, medium and high dose groups has no significant difference (P < 0.05); the serum LDL-C content of the mice in the blank control group is not significantly different from that in the tartary buckwheat instant tablet and the high-dose group (P < 0.05), and the low-dose group is significantly different from that in the tartary buckwheat instant tablet (P < 0.05), which indicates that the serum LDL-C content is not significantly different from the normal level by the high-dose group dose setting and the serum LDL-C content is significantly different from the normal level by the low-dose group dose setting; the serum T-CHO content of the mice in the blank control group is not significantly different from that of the low-dose and medium-dose groups of the instant tartary buckwheat tablet (P < 0.05), and the high-dose groups are significantly different from that of the low-dose and medium-dose groups of the instant tartary buckwheat tablet (P < 0.01), which indicates that the serum T-CHO content is not significantly different from the normal level by the dose setting of the low-dose and medium-dose groups of the instant tartary buckwheat tablet, and the serum T-CHO content is significantly different from the normal level by the dose setting of the high-dose groups.
Table 4: influence of Tartary buckwheat instant tablet on blood lipid level of experimental mice
Group of HDL-C(mmol/L) LDL-C(mmol/L) TG(mmol/L) T-CHO(mmol/L)
Blank group 0.55±0.09aB 0.99±0.41aA 1.32±0.21aA 3.06±0.23bcBC
Low dose 0.53±0.03aAB 1.37±0.20aB 1.38±0.12aA 3.22±0.47bcBC
Medium dosage 0.56±0.12aB 1.28±0.23aAB 1.30±0.21aA 2.82±0.41abAB
High dose 0.57±0.08aB 1.10±0.30aAB 1.23±0.12aA 2.43±0.17aA
Model 0.44±0.09aA 1.38±0.38aB 1.94±0.39bB 3.43±0.59cC
Note that: capitalized space represents the difference in significance at P < 0.05; the lowercase letter indicates a significant difference at P < 0.01. The same astronomical mother has no significant difference.
2.5.3 Effect of Tartary buckwheat Ready-to-eat tablet on the antioxidant level of hyperlipidemic mice
As can be seen from Table 5, the model group showed a very significant difference (P < 0.01) from the liver tissue MDA, GSH, SOD of the mice in the blank group after eight weeks of continuous gastric lavage, which showed that the modeling was successful.
The MDA level of the liver tissue of the model group mice is higher than that of the low, medium and high dose groups of the instant tartary buckwheat slices, and the difference (P < 0.01) is extremely remarkable, which indicates that the instant tartary buckwheat slices have the effect of reducing the MDA content of the liver tissue of the mice with hyperlipidemia; the GSH level of liver tissue of the model group mice has extremely significant difference (P < 0.01) with the low, medium and high dosage groups of the instant tartary buckwheat slices, which shows that the instant tartary buckwheat slices have the effect of improving the MDA content of liver tissue in the hyperlipidemic mice; compared with the mice in the model group, the liver tissue SOD level of the low, medium and high dose groups of the instant tartary buckwheat tablet is obviously increased, and has extremely obvious difference (P is less than 0.01), which indicates that the instant tartary buckwheat tablet has obvious effect on improving the liver tissue SOD level of the mice with hyperlipidemia.
Compared with the mice in the blank control group, the liver tissue GSH content of the tartary buckwheat instant tablet in the low, medium and high dose groups has no significant difference (P < 0.05); the liver tissue MDA content of the mice in the blank control group is not significantly different from that of the low-dose and medium-dose groups of the tartary buckwheat instant tablets (P < 0.05), and the high-dose groups are significantly different from those of the low-dose and medium-dose groups (P < 0.01), which indicates that the liver tissue MDA content of the tartary buckwheat instant tablets is not significantly different from the normal level by the dose setting of the low-dose and medium-dose groups, and the liver tissue MDA content of the high-dose groups is significantly different from the normal level by the dose setting of the high-dose groups; the liver tissue SOD content of the mice in the blank control group is not significantly different from that of the high-dose group of the tartary buckwheat instant tablet (P < 0.05), while the liver tissue SOD content of the mice in the medium-dose group is significantly different from that of the high-dose group (P < 0.05), and the liver tissue SOD content of the tartary buckwheat instant tablet is significantly different from that of the normal level (P < 0.01), so that the liver tissue SOD content of the mice in the low-dose group and the liver tissue SOD content of the tartary buckwheat instant tablet are significantly different from the normal level.
Table 5: influence of Tartary buckwheat instant tablet on antioxidant level of liver tissue of experimental mouse
Group of MDA(nmol/mg) GSH(umol/g) SOD(U/mg)
Blank group 1.32±0.35bB 368.65±91.67aA 57.55±4.43aA
Low dose 1.57±0.27bB 388.39±26.25aA 46.75±8.31bC
Medium dosage 1.35±0.26bB 389.83±39.65aA 50.31±6.23abBC
High dose 0.71±0.07aA 397.26±93.32aA 54.61±5.56abAB
Model 2.38±0.37cC 289.47±36.84bB 36.78±4.59cD
Note that: capitalized space represents the difference in significance at P < 0.05; the lowercase letter indicates a significant difference at P < 0.01. The same astronomical mother has no significant difference.
As can be seen from Table 6, after eight weeks of continuous gastric lavage, the model group showed very significant differences (P < 0.01) between the MDA and SOD in whole blood from mice in the blank group, and it was statistically significant, indicating successful molding.
The MDA level of whole blood of the mice in the model group is higher than that of the mice in the high-dose group in the tartary buckwheat instant tablet, has extremely significant difference (P < 0.01),
the low dose group of the instant tartary buckwheat tablet has no obvious difference with the low dose group of the instant tartary buckwheat tablet, which shows that the medium and high dose groups of the instant tartary buckwheat tablet have the effect of reducing the MDA content of whole blood of a hyperlipidemic mouse; the GSH level of the whole blood of the mice in the model group is not obviously different from that of the instant tartary buckwheat tablet in low, medium and high dosage groups, which shows that the instant tartary buckwheat tablet has no obvious effect on the MDA content of the whole blood in the mice with hyperlipidemia; compared with the mice in the model group, the instant tartary buckwheat tablet has obviously increased SOD level in whole blood in low, medium and high dose groups, has extremely obvious difference (P < 0.01), and shows that the instant tartary buckwheat tablet has obvious effect on improving the SOD level in whole blood of the mice with hyperlipidemia.
Compared with mice in a blank control group, the low, medium and high dose groups of the instant tartary buckwheat slices have no significant difference (P < 0.05) in the MDA content of whole blood, which indicates that the dose setting of the low, medium and high dose groups of the instant tartary buckwheat slices ensures that the MDA content of whole blood is not bright with the normal level
Displaying the difference; the blank control group mice have no significant difference between GSH content and the low, medium and high dosage groups of the instant tartary buckwheat tablet (P < 0.05), which indicates that the dosage of the low, medium and high dosage groups of the instant tartary buckwheat tablet is set so that the GSH content of the whole blood has no significant difference from the normal level; the mice in the blank control group have no significant difference (P < 0.05) between the SOD content of the mice and the high-dose group of the tartary buckwheat instant tablet, and have extremely significant difference (P < 0.01) between the SOD content of the mice and the high-dose group of the tartary buckwheat instant tablet, which indicates that the SOD content of the whole blood has no significant difference from the normal level by the dose setting of the high-dose group of the tartary buckwheat instant tablet, and the SOD content of the whole blood has significant difference from the normal level by the dose setting of the low-dose group and the medium-dose group.
Table 6: influence of Tartary buckwheat instant tablet on antioxidant level of whole blood of experimental mouse
Note that: capitalized space represents the difference in significance at P < 0.05; the lowercase letter indicates a significant difference at P < 0.01. The same astronomical mother has no significant difference.
Hyperlipidemia, also known as lipid metabolism disorder or abnormality, is a factor that causes various diseases such as fatty liver and atherosclerosis, and has a close relationship with the formation of diseases such as diabetes, fatty liver, hypertension, atherosclerosis, etc. Long-term diet of high-fat, high-calorie foods is an important cause of obesity and hyperlipidemia. With the aging, the organism is aged continuously, the oxidation resistance in the organism is reduced, and the capability of scavenging free radicals is weakened. The activities of superoxide dismutase and reduced glutathione in the body directly reflect the body's ability to scavenge free radicals. It has been found that a large number of free radicals are generated in the body due to the disruption of the balance of the oxidation system and the antioxidant system, and these free radicals can react further to form malondialdehyde, so that it is ultimately an important indicator for evaluating the degree of lipid peroxidation in the body.
Animal experiments carried out by taking the instant tartary buckwheat slices as experimental materials show that the instant tartary buckwheat slices have good blood fat reducing and antioxidant effects, can reduce the contents of serum low-density lipoprotein cholesterol, triglyceride and total cholesterol, improve the level of high-density lipoprotein cholesterol, reduce the content of malondialdehyde in liver tissues and whole blood, and improve the level of superoxide dismutase and reduced glutathione. The test dosage setting also shows that the low dosage (200 mg/kg.d) of the tartary buckwheat instant tablet has unobvious blood lipid reducing and antioxidation effects, and the high dosage (800 mg/kg.d) easily causes the blood lipid level and antioxidation indexes to be different from the normal state. When the dosage is set to be the medium dosage (400 mg/kg.d), the effects of reducing blood fat and resisting oxidation are best, and the medicine can not only play a good role in treating hyperlipidemia, but also maintain the blood fat and resisting oxidation index at normal level.
Compared with the traditional tartary buckwheat tea, the tartary buckwheat instant tablet furthest reserves the nutritional ingredients in the tartary buckwheat, and is easy to control the ingested dosage, so that the tartary buckwheat instant tablet can exert the dietary therapy health-care capability to a greater extent. Meanwhile, the form of the instant tartary buckwheat tablet is easier to accept and eat by people, is favorable for further developing into health-care food or medicine, and has higher market value.
In the present specification, each embodiment is described in a progressive manner, and each embodiment is mainly described in a different point from other embodiments, and identical and similar parts between the embodiments are all enough to refer to each other. For the device disclosed in the embodiment, since it corresponds to the method disclosed in the embodiment, the description is relatively simple, and the relevant points refer to the description of the method section.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.

Claims (3)

1. The instant composite tartary buckwheat tablet is characterized by comprising the following raw materials in parts by weight: 250-350 parts of tartary buckwheat instant tablet base powder, 25-35 parts of microcrystalline fiber, 20-28 parts of isomaltulose, 15-23 parts of fructo-oligosaccharide, 10-18 parts of tartary buckwheat whole plant fermentation liquor, 2-6 parts of isomaltooligosaccharide, 2-6 parts of galactosyl mannose, 0.5-1.5 parts of aloe vera gel, 0.5-1.5 parts of tragacanth gel and 0.2-0.7 part of sodium hyaluronate;
the tartary buckwheat instant tablet base powder comprises the following components in parts by weight: 15-25 parts of tartary buckwheat powder, 5-15 parts of millet powder, 3-8 parts of pumpkin powder, 3-8 parts of bitter gourd powder, 1-3 parts of liquorice, 1-3 parts of poria cocos, and 0.5-1.5 parts of rhizoma polygonati;
the whole tartary buckwheat strain fermentation liquor comprises the following raw materials in parts by weight: 4-6 parts of tartary buckwheat rice, 1.5-2.5 parts of tartary buckwheat root and 0.5-1.5 parts of tartary buckwheat leaf;
the production method of the compound tartary buckwheat instant tablet comprises the following steps:
step 1, preparing a whole tartary buckwheat strain fermentation liquor; mixing semen Fagopyri Esculenti, radix Et rhizoma Fagopyri Tatarici and folium Et rhizoma Fagopyri Tatarici, pulverizing, adding Aspergillus niger, yeast and lactobacillus, fermenting for 24-30 days to obtain radix Et rhizoma Fagopyri Tatarici whole plant fermentation broth;
step 2, preparing the tartary buckwheat instant tablet base powder: mixing radix Et rhizoma Fagopyri Tatarici powder, semen Setariae powder, fructus Cucurbitae moschatae powder, fructus Momordicae Charantiae powder, radix Glycyrrhizae, poria, rhizoma Polygonati, adding water, extruding, puffing, aging, and pulverizing to obtain radix Et rhizoma Fagopyri Tatarici instant tablet base powder;
step 3, preparation of tartary buckwheat instant tablets: mixing instant radix Et rhizoma Fagopyri Tatarici tablet base powder, microcrystalline cellulose, isomaltulose, fructooligosaccharide, radix Et rhizoma Fagopyri Tatarici whole plant fermentation broth, isomaltooligosaccharide, galactosyl mannose, aloe gum, tragacanth, and sodium hyaluronate, adding water, shaping, slicing, and drying.
2. The instant composite tartary buckwheat tablet according to claim 1, wherein the tartary buckwheat rice, the tartary buckwheat roots and the tartary buckwheat leaves are uniformly mixed in the step 1, crushed and sieved by a 10-30-mesh sieve, and 1-3wt% of aspergillus niger, 3-9wt% of yeast and 0.2-0.3wt% of lactic acid bacteria are added for fermentation for 24-30 days.
3. The instant composite tartary buckwheat slice according to claim 1, wherein the step 2 is characterized in that a screw extrusion and puffing machine is used for extrusion, puffing and curing, the screw rotation speed of the screw extrusion and puffing machine is 250-350 r/min, the extrusion temperature is 150-200 ℃, the moisture content of materials is controlled to be 20-30%, and the gelatinization degree of products is 90-95%.
CN202211145004.XA 2022-09-20 2022-09-20 Composite tartary buckwheat instant tablet and production method thereof Active CN116058496B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211145004.XA CN116058496B (en) 2022-09-20 2022-09-20 Composite tartary buckwheat instant tablet and production method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211145004.XA CN116058496B (en) 2022-09-20 2022-09-20 Composite tartary buckwheat instant tablet and production method thereof

Publications (2)

Publication Number Publication Date
CN116058496A CN116058496A (en) 2023-05-05
CN116058496B true CN116058496B (en) 2024-04-05

Family

ID=86175789

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211145004.XA Active CN116058496B (en) 2022-09-20 2022-09-20 Composite tartary buckwheat instant tablet and production method thereof

Country Status (1)

Country Link
CN (1) CN116058496B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101856126A (en) * 2010-06-22 2010-10-13 西昌航飞苦荞科技发展有限公司 Fagopyrum tataricum food base stock, food or health-care food made by same and preparation method thereof
CN106261501A (en) * 2016-08-10 2017-01-04 汪辉鳌 Bitter Buckwheat Nutrition Powder and processing technology thereof
CN106722160A (en) * 2016-11-25 2017-05-31 陕西师范大学 A kind of bitter buckwheat bud chewable tablets with healthcare function and preparation method thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101856126A (en) * 2010-06-22 2010-10-13 西昌航飞苦荞科技发展有限公司 Fagopyrum tataricum food base stock, food or health-care food made by same and preparation method thereof
CN106261501A (en) * 2016-08-10 2017-01-04 汪辉鳌 Bitter Buckwheat Nutrition Powder and processing technology thereof
CN106722160A (en) * 2016-11-25 2017-05-31 陕西师范大学 A kind of bitter buckwheat bud chewable tablets with healthcare function and preparation method thereof

Also Published As

Publication number Publication date
CN116058496A (en) 2023-05-05

Similar Documents

Publication Publication Date Title
CN109549097A (en) A kind of health caring noodles with functions of reducing sugar and reducing fat
CN103783407A (en) Method for processing low-energy extruded meal replacement powder
CN106213444A (en) A kind of soy sauce and preparation method thereof
CN105614669A (en) Nutritional yeast dried noodles and production method thereof
CN109430344A (en) A kind of coarse cereals Fu tea cake having stomach invigorating and digestion promoting effects function is dry and preparation method thereof
CN102204649A (en) Healthcare food for regulating and stabilizing blood sugar and method for preparing same
CN103859290B (en) Sea-tangle, green gram health care steamed bun and preparation method thereof
CN107927092A (en) A kind of rose honey cake and preparation method thereof
CN110638038A (en) Medical formula nutritional meal replacement powder for controlling hyperglycemia and preparation method thereof
KR20100020862A (en) Method of preparing fermented liquid of garlic and chonggugjang
CN116058496B (en) Composite tartary buckwheat instant tablet and production method thereof
CN111406941A (en) Nutritional dietary compositions and edible products
CN105875727A (en) Rose face-caring bread and making method thereof
CN115444127A (en) Zero-sucrose instant white fungus thick soup with weight-losing and lipid-lowering effects
CN109007583A (en) A kind of instant fermentation congee of quinoa and preparation method thereof
CN104305173A (en) Health food for diabetics and preparation method thereof
CN109123370A (en) A kind of fermented type wheat bran dietary fiber chewable tablets and its preparation method and application
CN107927091A (en) A kind of fruit honey cake and preparation method thereof
CN114259012A (en) Populus euphratica alkali formula flour and preparation method thereof
CN113080449A (en) Pure natural plant solid meal replacement bag capable of reducing blood sugar, blood fat and blood viscosity
CN111406940A (en) Dietary fiber composition and edible product
CN110240995A (en) A kind of bitter buckwheat red yeast rice medlar health preserving vinegar and its production technology
CN104255922A (en) Health care milk suitable for three-high crowd to drink and preparation method of milk
CN108617951A (en) A kind of dendrobium candidum healthy fine dried noodles product
KR20050111460A (en) Hotteok dough containing nuts and hotteok making method using the hotteok dough

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant